Phaseline

Companies › SIGA Technologies

SIGA Technologies: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Infectious disease; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Smallpox and Mpox Vaccine (JYNNEOS)
Live attenuated vaccinia virus vaccine
–Phase 2SmallpoxJan 2027
Tecovirimat
Envelope phospholipase OPG057 inhibitor
–Phase 2Smallpox; MonkeypoxJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05597735TecovirimatPhase 3MonkeypoxInfectious diseaseSep 2026
NCT04957485TecovirimatPhase 2SmallpoxInfectious diseaseJan 2027
NCT04957485Smallpox and Mpox Vaccine (JYNNEOS)Phase 2SmallpoxInfectious diseaseJan 2027

From the company's SEC filings

Cash of $116m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Eveliqure Biotechnologies Sanaria Brii Biosciences CastleVax Medicago

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.